Abstract
The majority of drugs used to treat children are not labeled for use in children. The Best Pharmaceuticals for Children Act of 2002, re-authorized as the US FDA Amendments Act of 2007, directs the National Institutes of Health (NIH) to sponsor pediatric clinical trials of drugs lacking patent protection, if the FDA request for studies has been declined. The NIH is currently sponsoring 17 clinical studies. Challenges encountered include a paucity of investigators who are trained in pediatric clinical pharmacology; inadequate knowledge of the mechanisms of drug action in a growing child; and lack of pediatric formulations.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wilson JT. Pediatric pharmacology: who will test the drugs? J Pediatr 1972; 80(5): 855–7
FDAMA. FDA Modernization Act of 1997: CDER-related documents [online]. Available from URL: http://www.fda.gov/cder/fdama/default.htm [Accessed 2008 Dec 8]
FDA. Best Pharmaceuticals for Children Act [online]. Available from URL: http://www.fda.gov/opacom/laws/pharmkids/contents.html [Accessed 2008 Dec 9]
Eunice Kennedy Shriver National Institute of Child Health and Human Development. Best Pharmaceuticals for Children Act (BPCA) activities at NICHD [online]. Available from URL: http://bpca.nichd.nih.gov [Accessed 2008 Nov 17]
GPO. Authenicated US Government information: public law 110-85 — Sep 27,2007 — 121 stat. 823 [online]. Available from URL: http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=110_cong_public_laws&docid=f:publ085.110.pdf [Accessed 2008 Dec 8]
FedBizOpps.gov. Federal business opportunities [online]. Available from URL: https://www.fbo.gov [Accessed 2008 Dec 5]
BPCA. Eunice Kennedy Shriver National Institute of Child Health and Human Development [online]. Available from URL: http://bpca.nichd.nih.gov [Accessed 2008 Dec 5]
BPCA. Clinical trials [online]. Available from URL: http://bpca.nichd.nih.gov/ [Accessed 2008 Dec 8]
Nelson RM. Challenges in the conduct of emergency research in children: a workshop report. Am J Bioeth 2006; 6(6): W1–9
Witt KL, Shelby MD, Itchon-Ramos N, et al. Methylphenidate and amphetamine do not induce cytogenetic damage in lymphocytes of children with ADHD. J Am Acad Child Adolesc Psychiatry 2008; 47(12) 1375–83
European Medicines Agency (EMEA). Medicines for children: a brighter future for child health [online]. Available from URL: http://www.emea.europa.eu/htms/human/paediatrics/prioritylist.htm [Accessed 2008 Nov 17]
Cordis. Seventh Research Framework Programme [online] Available from URL: http://cordis.europa.eu/fp7/dc/index.cfm?fuseaction=UserSite.Coopera-tionDetailsCallPage&call_id=140 [Accessed 2008 Nov 17]
Giacoia GP, Mattison DR. Newborns and drug studies: the NICHD/FDA newborn drug development initiative. Clin Ther 2005; 27(6): 796–813
Kapogiannis BG, Mattison DR. Adolescents in Clinical Trials. Clin Pharmacol Ther 2008 Dec; 84(6): 655–9
Kearns GL, Ritschel WA, Wilson JT, et al. Clinical pharmacology: a discipline called to action for maternal and child health. Clin Pharmacol Ther 2007; 81(4): 463–8
Slikker Jr W, Young JF, Corley RA, et al. Improving predictive modeling in pediatric drug development: pharmacokinetics, pharmacodynamics, and mechanistic modeling. Ann N Y Acad Sci 2005; 1053: 505–18
Acknowledgements
No sources of funding were used to assist in the preparation of this article. The author has no conflicts of interest that are directly relevant to the content of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zajicek, A. The National Institutes of Health and the Best Pharmaceuticals for Children Act . Pediatr-Drugs 11, 45–47 (2009). https://doi.org/10.2165/0148581-200911010-00015
Published:
Issue Date:
DOI: https://doi.org/10.2165/0148581-200911010-00015